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by the characterization of phospholipase A2 re-
ceptor 1 and thrombospondin type-1 domain-
containing 7A (THSD7A) as podocyte antigens in 
membranous nephropathy, constitutes the most 
probable established mechanism for the forma-
tion of subepithelial deposits of immune com-
plexes.3,4 It is unclear whether the initial recog-
nition of antigens that leads to the formation of 
high-affinity antibodies occurs within the kidney 
or in other tissues, including malignant tumors. 
Antibodies that are produced in response to non-
renal targets may recognize the same or related 
molecules expressed on podocytes through a 
mechanism known as molecular mimicry.
Here we describe a 40-year-old woman who 
presented with THSD7A-associated membranous 
nephropathy (Fig. 1A and 1B, and Figs. S1 and S2 
in the Supplementary Appendix, available with 
the full text of this letter at NEJM.org). The condi-
tion was concomitant with the presence of mixed 
adenoneuroendocrine carcinoma of the gallblad-
der (Fig. S3A in the Supplementary Appendix). 
This study was approved by the local ethics com-
mittee of the chamber of physicians of Hamburg. 
The patient provided written informed consent.
The primary gallbladder tumor and corre-
sponding lymph-node metastases were positive 
for THSD7A on immunohistochemical analysis 
(Fig. 1C and 1D). Fluorescence in situ hybridiza-
tion assay revealed polysomy of chromosome 7, 
with six copies of THSD7A and the CEP7 chromo-
some 7 centromere (Fig. S3B in the Supplemen-
tary Appendix). The messenger RNA for THSD7A 
was detectable in the gallbladder carcinoma but 
not in the normal tissue of the gallbladder. Fol-
licular dendritic cells of lymph nodes with meta-
static infiltration were also positive for THSD7A 
(Fig. 1E, and Fig. S4 and S5 in the Supplementary 
Appendix). Follicular dendritic cells are unique 
stromal cells that present stored antigen to ma-
turing B cells for the formation of high-affinity 
antibodies.5
After chemotherapy, THSD7A antibodies in 
plasma were no longer detectable, and urinary 
protein excretion decreased from 5.0 to 0.7 g 
of protein per gram of creatinine (protein-to-
creatinine ratio) (Fig. 1A). Serum samples from 
1009 additional patients with membranous ne-
phropathy were screened, and 25 patients were 
found to be positive for THSD7A antibodies. Of 
these 25 patients, 7 (including the index patient) 
had a malignant tumor. These findings support 
a causal relationship between the new expression 
of THSD7A in a gallbladder carcinoma and the 
development of membranous nephropathy and 
may thus describe a potential mechanism for the 
association between cancer and membranous 
nephropathy.
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Visual Acuity after Retinal Gene Therapy for Choroideremia
To the Editor: Two recent clinical reports of 
retinal gene therapy with adeno-associated virus 
(AAV) vectors in patients with Leber’s congenital 
amaurosis showed initial gains in visual function 
that subsequently declined.1,2 We previously re-
ported early improvement in visual acuity in two 
of six patients who received retinal gene therapy 
in one eye (the study eye) to treat choroideremia,3 
a disease that is characterized by atrophy of the 
choriocapillaris and retinal pigment epithelium 
and involves vision loss that leads to blindness.
Choroideremia is caused by loss-of-function 
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mutations in the gene CHM. We delivered non-
mutated CHM in an AAV vector (AAV.REP1) by 
subfoveal injection into the vicinity of the retinal 
pigment epithelium and photoreceptor cells, the 
dysfunction of which is presumed to be a con-
tributing factor in vision loss. Here we report 
that the early improvement that we observed in 
two of the six patients was sustained at 3.5 years 
after treatment, despite progressive degeneration 
in the other eyes (the control eyes). The control 
eyes did not receive the intervention, and visual 
acuity in the control eyes was better than the 
visual acuity in the study eyes at baseline.
The best corrected visual acuity was reported 
as the number of letters correctly read by the 
patient on an Early Treatment of Diabetic Reti-
nopathy Study (ETDRS) chart at 4 m. Two pa-
tients (Patients 1 and 4) had advanced disease, 
and the visual acuity in the study eyes at baseline 
in these patients was several lines below normal 
(each line contains 5 letters) on the ETDRS chart 
(Table 1). By 3.5 years, visual acuity in the treated 
study eye had increased by 21 letters (>4 lines) 
from baseline on the ETDRS chart in Patient 1 
and by 18 letters (>3 lines) in Patient 4. In con-
trast, over the same period, visual acuity in the 
control eyes decreased by 18 letters in Patient 1 
and by 6 letters in Patient 4.
A cataract developed in the study eye in Pa-
tient 4 at 2 years. This cataract was subsequent-
ly removed, but the removal was not the primary 
reason for the gain in visual acuity recorded at 
3.5 years. The visual acuity at 3.5 years was simi-
lar to the level recorded 12 months after surgery, 
before the cataract was clinically significant.
The other four patients had good visual acuity 
at baseline and therefore a limited scope for im-
provement. Patient 3, the youngest patient, had 
the largest area of surviving retina and the best 
pretreatment visual acuity — 20/16 (89 ETDRS 
letters). This visual acuity returned to the base-
line level 12 months after the administration of 
gene therapy and was sustained until the last 
follow-up. No loss of visual acuity was observed in 
the untreated control eye during this time, proba-
bly because the disease was still in the early stages. 
However, the treated eye of Patient 3 did show 
improvement on an electrophysiological study. 
This test measures a global macular response 
and may therefore be more relevant in younger 
patients with larger areas of surviving retina 
(Fig. S3 in the Supplementary Appendix, available 
with the full text of this letter at NEJM.org).
The levels of visual acuity in the study eyes in 
Patients 2, 5, and 6 all returned to baseline levels 
by 6 months after treatment, but by the 3.5-year 
follow-up, the visual acuity of the study and 
control eyes in Patient 6 had declined by 29 and 
18 letters, respectively. Patient 6 received a lower 
total vector dose than the other patients in the 
trial; we speculate that the loss of visual acuity 
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1 1×1010 23 58 41 62 44 40 21 −18  39
2 1×1010 79 82 73 77 77 72 −2 −10   8
3 1×1010 89 85 94 85 90 86 1 1   0
4 1×1010 53 76 61 70 71 70 18 −6  24
5 1×1010 79 83 76 78 83 72 4 −11  15
6 6×109 84 88 69 84 55 70 −29 −18 −11
*  The best corrected visual acuity was reported as the number of letters correctly read by the patient on an Early Treatment of Diabetic Retinop‑
athy Study chart at 4 m. Patients 2, 4, 5, and 6 underwent cataract surgery after the 2‑year follow‑up visit. Cataracts developed in all patients, 
and they reported subjective vision change. Ocular hypertension in both eyes also developed in Patient 3. Additional details are provided in 
Table S1 in the Supplementary Appendix.
†  The injection volume of AAV.REP1 was 0.1 ml in Patients 1 through 5 and 0.06 ml in Patient 6. The abbreviation vg denotes vector genomes.
Table 1. Visual Acuity in Patients with Choroideremia Who Received Retinal Gene Therapy.*
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eration of cells in the fovea rather than a toxic 
effect of the vector. In contrast, at the 3.5-year 
follow-up, the visual acuity in the injected eyes 
in Patients 2 and 5 remained close to that at 
baseline, whereas the visual acuity of the control 
eye was lower by 10 and 11 letters, respectively.
Best corrected visual acuity is a reliable marker 
of visual function. In contrast to Leber’s congeni-
tal amaurosis, in which visual acuity is generally 
profoundly affected early in life, choroideremia 
and most types of retinitis pigmentosa are char-
acterized by progressive loss of the visual field, 
with visual acuity remaining close to normal 
levels until the very late stages of disease. There-
fore, in some patients, the effect of preserving 
visual acuity with the use of retinal gene therapy 
may take several years to become apparent.
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